膀胱肿瘤是最常见的泌尿系统肿瘤,其中上皮性肿瘤占95%以上,绝大多数为尿路移行上皮细胞癌。膀胱癌的早期症状不明显,复发率较高,早期诊断和治疗对提高其疗效非常重要。近年来,诊断膀胱肿瘤的新方法不断出现,显著提高了膀胱肿瘤诊断及预后预测水平。其中,膀胱肿瘤标记物检测已成为膀胱肿瘤的诊断新方法,具有十分重要的临床意义。研究发现,细胞角蛋白20(cytokeratin 20,CK20)是中间纤维家族成员之一,在正常膀胱组织中特异性表达于伞细胞,在膀胱癌中特异性表达于膀胱移行细胞癌,其诊断膀胱肿瘤的特异性和灵敏性均较高,且与膀胱肿瘤的临床分级、病理分期和转移均密切相关,因此可作为辅助诊断膀胱肿瘤的检测标志物及治疗和预后评估指标。本文将就其在膀胱癌中的研究进展综述如下。 Bladder cancer is the most common urological tumors, of which epithelial tumors accounted for more than 95%, the vast majority of urinary tract transitional cell carcinoma. Early symptoms of bladder cancer is not obvious, the recurrence rate is high, early diagnosis and treatment to improve its efficacy is very important. In recent years, new methods of diagnosis of bladder cancer continue to appear, significantly improving the diagnosis of bladder cancer and prognosis of the level. Among them, the detection of bladder tumor markers has become a new diagnostic method of bladder cancer, has a very important clinical significance. It is found that cytokeratin 20 (CK20), a member of the intermediate fiber family, is expressed specifically in umbrella cells in normal bladder tissue and specifically in transitional cell carcinoma of the bladder in bladder cancer, which diagnoses bladder cancer It has high specificity and sensitivity and is closely related to the clinical grade, pathological stage and metastasis of bladder neoplasms. Therefore, it can be used as a diagnostic marker and a therapeutic and prognostic indicator in the diagnosis of bladder cancer. This article reviews its progress in bladder cancer as follows.